RenovoRx, Inc. RNXT
We are a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration ("FDA")-cleared local drug-delivery device, targeting high unmet medical needs. Our mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of therapeutic agents.
Our patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform, enabled by RenovoCath, is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial , or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy. Our novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $43.0K | — | — | — | — | — |
| Cost of revenue | $327.0K | $0 | — | — | — | — | — |
| Gross profit | $796.0K | $43.0K | — | — | — | — | — |
| R&D | $6.3M | $6.0M | $5.7M | $4.3M | $3.0M | $2.4M | — |
| SG&A | $7.0M | $5.0M | $5.7M | $5.6M | $2.6M | $818.0K | — |
| Total operating expenses | $13.3M | $11.0M | $11.4M | $9.9M | $5.7M | $3.2M | — |
| Operating income | -$12.5M | -$11.0M | -$11.4M | -$9.9M | -$5.7M | -$3.2M | — |
| Interest expense | — | — | — | — | $834.0K | $587.0K | — |
| Pre-tax income | -$11.2M | -$8.8M | — | — | — | — | — |
| Income tax | $2.0K | — | — | — | — | — | — |
| Net income | -$11.2M | -$8.8M | -$10.2M | -$9.9M | -$6.3M | -$3.8M | — |
| EPS, basic | -0.32 | -0.40 | -0.99 | -1.09 | -1.21 | — | — |
| EPS, diluted | -0.32 | -0.40 | -0.99 | -1.09 | -1.21 | -1.72 | — |
| Shares, diluted (wtd. avg.) | $35.3M | $22.3M | $10.3M | $9.1M | $5.2M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.0M | $7.2M | $1.2M | $4.4M | $15.2M | $1.8M | — |
| Short-term investments | — | — | — | $2.0M | — | — | — |
| Receivables | $139.0K | $43.0K | — | — | — | — | — |
| Inventory | $189.0K | $0 | — | — | — | — | — |
| Total current assets | $7.9M | $7.8M | $1.5M | $7.3M | $16.3M | $1.9M | — |
| Property, plant and equipment | $12.0K | $12.0K | — | — | — | — | — |
| Total assets | $8.1M | $8.1M | $1.5M | $7.3M | $16.3M | $1.9M | — |
| Accounts payable | $799.0K | $586.0K | $561.0K | $534.0K | $525.0K | $162.0K | — |
| Total current liabilities | $2.0M | $1.9M | $1.2M | $1.1M | $938.0K | $4.1M | — |
| Total liabilities | $2.7M | $3.6M | $4.5M | $1.1M | $938.0K | $4.1M | — |
| Retained earnings | -$61.4M | -$50.2M | -$41.4M | -$31.2M | -$21.3M | -$15.0M | — |
| Total equity | $5.4M | $4.5M | $3.0M | $6.2M | $15.3M | -$14.7M | -$10.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.0M | -$9.1M | -$10.3M | -$8.8M | -$5.9M | -$3.5M | — |
| Depreciation and amortisation | $2.0K | $0 | — | — | — | — | — |
| Stock-based compensation | $1.3M | $1.2M | $1.1M | $644.0K | $147.0K | $33.0K | — |
| Capital expenditure | $2.0K | $12.0K | — | — | — | — | — |
| Investing cash flow | -$2.0K | -$12.0K | $2.0M | -$2.0M | -$15.0K | — | — |
| Financing cash flow | $10.8M | $15.1M | $5.0M | $42.0K | $19.3M | $3.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-227256.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |